Key Highlights

  • Bright Minds shares are trading down 53.65% at $25.49, against a previous close of $54.98.
  • FDA placed a partial clinical hold on the planned BMB-101 Phase 2 trial in DEEs.
  • Company expects the full FDA hold letter within 30 days.

Bright Minds (NASDAQ:DRUG) shares are trading down 53.65% at $25.49, against a previous close of $54.98, after the company disclosed that the FDA placed a partial clinical hold on its IND for BMB-101 in developmental and epileptic encephalopathies. Trading was halted pre-market, and the stock is now near its 52-week low of $18.90 on Volume well above average.

Bright Minds, based in New York, is a clinical-stage, pre-revenue biotechnology company developing selective serotonin 5-HT2 receptor agonists for epilepsy and other central nervous system disorders. Its lead candidate, BMB-101, is a 5-HT2C Gq-biased agonist in Phase 2 development for developmental and epileptic encephalopathies and absence epilepsies. The pipeline also includes BMB-105 for Prader-Willi syndrome and the preclinical BMB-201 and BMB-202.

What the FDA Said

The FDA notified the company by email that the IND for developmental and epileptic encephalopathies and related Protocol BMB-101-105 has been placed on partial clinical hold. The proposed trial is a randomized, placebo-controlled, double-blind Phase 2 study evaluating ascending doses of BMB-101, up to a maximum tolerated dose, for seizures associated with these conditions.

The primary reason given by the FDA relates to identified toxicity in mice, and to inadequate pharmacokinetic and juvenile toxicity data to support the proposed pediatric enrollment.

The Company's Position

Bright Minds believes the hold covers only the planned Phase 2 trial in the United States and does not affect its other ongoing clinical trials. It also believes the mouse toxicity was not seen in any other species and, citing its toxicology reports, peer reviewers and multiple independent expert opinions, considers the findings incidental and not drug-related.

The company states these are its own beliefs and should not be read as FDA findings or as resolving the agency's concerns. It is waiting for the full hold letter, which the FDA said it would provide within 30 days with additional details, non-hold recommendations and study-design recommendations. Bright Minds plans to request clarification immediately and then refine the study in line with the FDA's recommendations.

Market Reaction and What Comes Next

The stock has fallen to a level near the bottom of a 52-week range of $18.90 to $123.75, which shows how much value the market has removed from a company with a single lead asset. The company noted that additional data or studies may be required and that there is no assurance on when the hold will be lifted or whether future U.S. trials will be allowed to proceed.

Bright Minds has about 26 employees and relies on Equity Financing and potential partnering or licensing to fund research and development. It is listed on both the Canadian Securities Exchange and Nasdaq under the symbol DRUG. The decline appears specific to the stock, since the broader market and the healthcare sector are firm.

The company raised $175 million in January, which may cushion its Balance Sheet while it works through the issue. The key points to watch are the content of the FDA letter within 30 days, whether the agency's concerns can be met with additional pharmacokinetic and juvenile toxicity data, and the timeline for restarting the planned Phase 2 trial. Until the letter arrives, uncertainty over the path for BMB-101 in this patient group is likely to remain the main driver of the stock.